|
1
|
Chen S: Essential hypertension:
Perspectives and future directions. J Hypertens. 30:42–45. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chinese National Center for Cardiovascular
Diseases (CNCCD), . Report on Cardiovascular Diseases in China.
2013.
|
|
3
|
Sheng CS, Liu M, Kang YY, Wei FF, Zhang L,
Li GL, Dong Q, Huang QF, Li Y and Wang JG: Prevalence, awareness,
treatment and control of hypertension in elderly Chinese. Hypertens
Res. 36:824–828. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lim SS, Vos T, Flaxman AD, Danaei G,
Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee
M, et al: A comparative risk assessment of burden of disease and
injury attributable to 67 risk factors and risk factor clusters in
21 regions, 1990–2010: A systematic analysis for the Global Burden
of Disease Study 2010. Lancet. 380:2224–2260. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tibazarwa KB and Damasceno AA:
Hypertension in developing countries. Can J Cardiol. 30:527–533.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yancy CW, Jessup M, Bozkurt B, Butler J,
Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi
JL, et al: 2013 ACCF/AHA guideline for the management of heart
failure: A report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice
Guidelines. J Am Coll Cardiol. 62:e147–e239. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McAlister FA, Wiebe N, Ezekowitz JA, Leung
AA and Armstrong PW: Meta-analysis: Beta-blocker dose, heart rate
reduction, and death in patients with heart failure. Ann Intern
Med. 150:784–794. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Materson BJ, Reda DJ, Cushman WC, Massie
BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R and
Gottdiener J: Single-drug therapy for hypertension in men. A
comparison of six antihypertensive agents with placebo. The
Department of Veterans Affairs Cooperative Study Group on
Antihypertensive Agents. N Engl J Med. 328:914–921. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Johnson JA and Liggett SB: Cardiovascular
pharmacogenomics of adrenergic receptor signaling: Clinical
implications and future directions. Clin Pharmacol Ther.
89:366–378. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bijl MJ, Visser LE, van Schaik RH, Kors
JA, Witteman JC, Hofman A, Vulto AG, van Gelder T and Stricker BH:
Genetic variation in the CYP2D6 gene is associated with a lower
heart rate and blood pressure in beta-blocker users. Clin Pharmacol
Ther. 85:45–50. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou SF: Polymorphism of human cytochrome
P450 2D6 and its clinical significance: Part II. Clin
Pharmacokinet. 48:761–804. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu D, Li G, Deng M, Song W, Huang X, Guo
X, Wu Z, Wu S and Xu J: Associations between ADRB1 and CYP2D6 gene
polymorphisms and the response to β-blocker therapy in
hypertension. J Int Med Res. 43:424–434. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yuan H, Huang Z, Yang G, Lv H, Sang H and
Yao Y: Effects of polymorphism of the beta(1) adrenoreceptor and
CYP2D6 on the therapeutic effects of metoprolol. J Int Med Res.
36:1354–1362. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rockman HA, Koch WJ and Lefkowitz RJ:
Seven- transmembrane-spanningreceptors and heart function. Nature.
415:206–212. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang Q, Yuan H, Xing X, Liu J, Huang Z
and Du X: Methylation of adrenergic β1 receptor is a potential
epigenetic mechanism controlling antihypertensive response to
metoprolol. Indian J Biochem Biophys. 48:301–307. 2011.PubMed/NCBI
|
|
16
|
Liu H, Xing X, Huang L, Huang Z and Yuan
H: The expression level of myocardial β1-adrenergic receptor
affects metoprolol antihypertensive effects: A novel mechanism for
interindividual difference. Med Hypotheses. 81:71–72. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vandenberghe LH, Xiao R, Lock M, Lin J,
Korn M and Wilson JM: Efficient serotype-dependent release of
functional vector into the culture medium during adeno-associated
virus manufacturing. Hum Gene Ther. 21:1251–1257. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mueller C, Ratner D, Zhong L, Esteves-Sena
M and Gao G: Production and discovery of novel recombinant
adeno-associated viral vectors. Curr Protoc Microbiol. Chapter 14:
Unit14D.1. 2012. View Article : Google Scholar
|
|
19
|
Wu XB, Dong XY, Wu ZJ, Cao H, Niu DB, Qu
JG, Wang H and Hou YD: A novel method for purification of
recombinant adenoassociated virus vectors on a large scale. Chinese
Sci Bull. 46:pp485–488. 2001. View Article : Google Scholar
|
|
20
|
McClure C, Cole KL, Wulff P, Klugmann M
and Murray AJ: Production and titering of recombinant
adeno-associated viral vectors. J Vis Exp. e33482011.PubMed/NCBI
|
|
21
|
Bish LT, Sweeney HL, Müller OJ and
Bekeredjian R: Adeno-associated virus vector delivery to the heart.
Methods Mol Biol. 807:219–237. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Katz MG, Swain JD, Tomasulo CE, Sumaroka
M, Fargnoli A and Bridges CR: Current strategies for myocardial
gene delivery. J Mol Cell Cardiol. 50:766–776. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Naya M, Tsukamoto T, Morita K, Katoh C,
Nishijima K, Komatsu H, Yamada S, Kuge Y, Tamaki N and Tsutsui H:
Myocardial beta-adrenergic receptor density assessed by
11C-CGP12177 PET predicts improvement of cardiac function after
carvedilol treatment in patients with idiopathic dilated
cardiomyopathy. J Nucl Med. 50:220–225. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ferrara N, Komici K, Corbi G, Pagano G,
Furgi G, Rengo C, Femminella GD, Leosco D and Bonaduce D:
β-adrenergic receptor responsiveness in aging heart and clinical
implications. Front Physiol. 4:3962014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hellgren I, Sylven C and Magnusson Y:
Study of the beta1 adrenergic receptor expression in human tissues:
Immunological approach. Biol Pharm Bull. 23:700–703. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Oliver E, Rovira E, Montó F, Valldecabres
C, Julve R, Muedra V, Ruiz N, Barettino D and D'Ocon P:
beta-Adrenoceptor and GRK3 expression in human lymphocytes is
related to blood pressure and urinary albumin excretion. J
Hypertens. 28:1281–1289. 2010.PubMed/NCBI
|
|
28
|
Hamdani N and Linke WA: Alteration of the
beta-adrenergic signaling pathway in human heart failure. Curr
Pharm Biotechnol. 13:2522–2531. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Arnold AS, Tang YL, Qian K, Shen L,
Valencia V, Phillips MI and Zhang YC: Specific beta1-adrenergic
receptor silencing with small interfering RNA lowers high blood
pressure and improves cardiac function in myocardial ischemia. J
Hypertens. 25:197–205. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang YC, Bui JD, Shen L and Phillips MI:
Antisense inhibition of beta(1)-adrenergic receptor mRNA in a
single dose produces a profound and prolonged reduction in high
blood pressure in spontaneously hypertensive rats. Circulation.
101:682–688. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim SM, Huang Y, Qin Y, Mizel D,
Schnermann J and Briggs JP: Persistence of circadian variation in
arterial blood pressure in beta1/beta2-adrenergic
receptor-deficient mice. Am J Physiol Regul Integr Comp Physiol.
294:R1427–R1434. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yoo B, Lemaire A, Mangmool S, Wolf MJ,
Curcio A, Mao L and Rockman HA: Beta1-adrenergic receptors
stimulate cardiac contractility and CaMKII activation in vivo and
enhance cardiac dysfunction following myocardial infarction. Am J
Physiol Heart Circ Physio. l297:H1377–H1386. 2009. View Article : Google Scholar
|
|
33
|
Ecker PM, Lin CC, Powers J, Kobilka BK,
Dubin AM and Bernstein D: Effect of targeted deletions of beta1-
andbeta2-adrenergic-receptor subtypes on heart rate variability. Am
J Physiol Heart Circ Physiol. 290:H192–H199. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen SJ, Johnston J, Sandhu A, Bish LT,
Hovhannisyan R, Jno-Charles O, Sweeney HL and Wilson JM: Enhancing
the utility of adeno-associated virus gene transfer through
inducible tissue-specific expression. Hum Gene Ther Methods.
24:270–278. 2013. View Article : Google Scholar : PubMed/NCBI
|
